Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOYA: Obinutuzumab vs Rituximab with CHOP in DLBCL
NCT01287741Phase 3Terminated
- Sponsor
- Roche
- Start
- Jul 2011
- Primary completion
- Apr 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 29
01
Overview
A Phase 3 trial of obinutuzumab in diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Started Jul 2011; status: terminated.
02
Drugs
obinutuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01287741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01287741.